Vimta Labs Limited — Investor Meet, 10-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Vimta Labs reported strong Q2 FY26 financial results: Total Income ₹104.5 Cr (+22.3% YoY) and PAT ₹19.9 Cr (+17.1% YoY), marking its highest-ever quarterly sales. Pharma research & testing and food services were key growth drivers. Management remains confident in achieving its ₹500 Cr FY26 revenue target, with no immediate capacity constraints following recent infrastructure expansion. The Biologics CR&D project is on schedule for Q1 FY27 commercialization, integrating services for large molecule development with ~₹25 Cr capex planned annually. The company focuses on global business development, adopting new technologies, and sees strong demand in the outsourcing segment.